Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

#HBV

Home » #HBV
AASLD 2024丨Dr. Xiaohong Gao: Initiating TDF at Different Gestational Weeks Safely Prevents HBV Mother-to-Child Transmission

AASLD 2024丨Dr. Xiaohong Gao: Initiating TDF at Different Gestational Weeks Safely Prevents HBV Mother-to-Child Transmission

Posted by By Lisa Cui 2024.12.06
Despite extensive research, there remains no universal consensus on the optimal timing for initiating antiviral therapy during pregnancy to prevent hepatitis B virus (HBV) mother-to-child transmission (MTCT). Divergent recommendations have…
Read More
AASLD Voice of China | Dr. Chao Wu and Dr. Jie Li’s Team at Nanjing Drum Tower Hospital Focus on Non-invasive Diagnosis

AASLD Voice of China | Dr. Chao Wu and Dr. Jie Li’s Team at Nanjing Drum Tower Hospital Focus on Non-invasive Diagnosis

Posted by By Lisa Cui 2024.01.18
Risk Factors, and Treatment Management of Hepatitis, Yielding Fruitful Results! Editor's Note: Hepatitis B virus (HBV) infection is a widespread global health issue. According to the World Health Organization, as…
Read More
Recent Posts
  • ASCO China Voice | Zhenzhen Liu: HELEN Series Studies Presented at ASCO Advance Precision Treatment Strategies for Breast Cancer
  • ASCO China Voice | Xiaowei Qi: Pembrolizumab-Free Anthracycline-Sparing Neoadjuvant Regimen with Penpulimab, Taxane, and Carboplatin Demonstrates Promising Efficacy and Safety in Triple-Negative Breast Cancer
  • ASCO China Voice | Zhimin Shao and Zhonghua Wang’s Team: IRIS-A Study Demonstrates That Capecitabine Plus Trastuzumab Provides Effective, Low-Toxicity De-escalated Adjuvant Therapy for Stage IA HER2-Positive Breast Cancer
  • ASCO China Voice | Jiong Wu: PANKU-Breast02 Meets Both PFS and OS Primary Endpoints, with Iza-Bren Delivering a New Breakthrough for Previously Treated Advanced Triple-Negative Breast Cancer
  • ASCO China Voice | Professor Hui Xie: BMI May Serve as a Simple Stratification Marker for Trastuzumab Deruxtecan in Advanced Breast Cancer
Recent Comments
    Archives
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top